Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 17;10(24):5938.
doi: 10.3390/jcm10245938.

Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists

Jean Ferrières  1 , François Roubille  2 , Michel Farnier  3 , Patrick Jourdain  4 , Denis Angoulvant  5 , Franck Boccara  6 , Nicolas Danchin  7
Affiliations

Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists

Jean Ferrières et al. J Clin Med. .

Abstract

Introduction: Patients with established coronary artery disease (CAD) are at very high risk for cardiovascular events.

Methods: The DAUSSET study is a national, multicenter, non-interventional study that included very high-risk CAD patients followed by French cardiologists. It aimed to describe real-life clinical practices for low-density lipoprotein (LDL) cholesterol control in the secondary prevention of CAD.

Results: A total of 912 patients (mean age, 65.4 years; men, 76.1%; myocardial infarction, 69.4%; first episode, 80.1%) were analyzed. The LDL cholesterol goal was 70 mg/dL in most cases (84.9%). The LDL cholesterol goal <70 mg/dL was achieved in 41.7% of patients. Of the 894 (98.0%) patients who received lipid-lowering therapy, 81.2% had been treated more intensively after the cardiac event, 27.0% had been treated less intensively and 13.1% had been maintained. Participating cardiologists were very satisfied or satisfied with treatment response in 72.6% of patients. Moderate satisfaction or dissatisfaction with lipid-lowering therapy was related to not achieving objectives (100%), treatment inefficacy (53.7%), treatment intolerance (23.4%) and poor adherence (12.3%).

Conclusion: These real-world results show that lipid control in very high-risk patients remains insufficient. More than half of the patients did not achieve the LDL cholesterol goal. Prevention of cardiovascular events in these very high-risk patients could be further improved by better education and more intensive lipid-lowering therapy.

Keywords: coronary artery disease; dyslipidemia; guidelines adherence; hypercholesterolemia; myocardial infarction; secondary prevention.

PubMed Disclaimer

Conflict of interest statement

J. Ferrières has received consulting fees from Amgen, Akcea, Boehringer, Sanofi and Servier. F. Roubille has received consulting fees from Abbott, Air Liquide, Amgen, AstraZeneca, Bayer, Boehringer, Medtronic, Novonordisk, Pfizer, Sanofi, Servier and Zoll, and research grants from AstraZeneca. M. Farnier has received consulting fees from Abbott, Amarin, Amgen, AstraZeneca, Austell, Merck, Mylan, Pfizer, Sanofi and Servier. P. Jourdain has nothing to declare. D. Angoulvant has received consulting fees from Amgen, Alnylam, Astra Zeneca, Bayer, Boehringer, BMS, Novartis, Novo Nordisk, Pfizer, Sanofi and Servier. F. Boccara has received consulting fees from Amgen, Gilead, MSD, Sanofi, Servier and ViiV Healthcare. N. Danchin reports having received grants, speaking fees, consulting fees or non-financial support from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Intercept, MSD, Novo-Nordisk, Pfizer, Sanofi, Servier, UCB and Vifor.

Figures

Figure 1
Figure 1
LDL-cholesterol at inclusion.
See this image and copyright information in PMC

References

    1. Boren J., Chapman M.J., Krauss R.M., Packard C.J., Bentzon J.F., Binder C.J., Daemen M.J., Demer L.L., Hegele R.A., Nicholls S.J., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2020;41:2313–2330. doi: 10.1093/eurheartj/ehz962. - DOI - PMC - PubMed
    1. Raygor V., Khera A. New recommendations and revised concepts in recent guidelines on the management of dyslipidemias to prevent cardiovascular disease: The 2018 ACC/AHA and 2019 ESC/EAS guidelines. Curr. Cardiol. Rep. 2020;22:87. doi: 10.1007/s11886-020-01331-z. - DOI - PubMed
    1. Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E., Hegele R.A., Krauss R.M., Raal F.J., Schunkert H., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017;38:2459–2472. doi: 10.1093/eurheartj/ehx144. - DOI - PMC - PubMed
    1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. - PubMed
    1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corra U., Cosyns B., Deaton C., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2016;37:2315–2381. - PMC - PubMed

Grants and funding

LinkOut - more resources